Drug Profile
EP 302
Alternative Names: AST-302; EP-302 - EpiThanyLatest Information Update: 04 Feb 2020
Price :
$50
*
At a glance
- Originator University of Washington
- Developer EpiThany
- Class Antigens; Antineoplastics; Cancer vaccines; Immunotherapies
- Mechanism of Action Th1 cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Breast cancer
Most Recent Events
- 05 Oct 2016 Preclinical trials in Breast cancer in USA (Parenteral) (EpiThany pipeline, October 2016)